Patents Assigned to Inserm
  • Patent number: 9439975
    Abstract: The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: September 13, 2016
    Assignees: Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite Joseph Fourier
    Inventor: Michel De Waard
  • Patent number: 9439981
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: September 13, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer
  • Patent number: 9439404
    Abstract: The present invention relates to a transgenic animal model system based on the development of transgenic mice bearing components of the human immune system. Specifically, the invention relates to a Flk2 deficient Rag?/??c?/? transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further provides methods for increasing the numbers of functionally competent human dendritic cells and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential immune adjuvants and for developing novel therapeutics.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: September 13, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), INSTITUT PASTEUR
    Inventors: James Di Santo, Jean-Jacques Mention
  • Publication number: 20160244424
    Abstract: The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.
    Type: Application
    Filed: September 24, 2014
    Publication date: August 25, 2016
    Applicants: UNIVERSITE DE RENNES 1, Centre national de la recherche scientifique, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mickael JEAN, Amélie FOUQUE, Patrick LEGEMBRE, Pierre VAN DE WEGHE
  • Publication number: 20160243194
    Abstract: The present invention relates to a viral vector for expression of the cell death-inducing PUMA protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the PUMA protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (CAR).
    Type: Application
    Filed: October 7, 2014
    Publication date: August 25, 2016
    Applicants: Hospices Civils de Lyon, The Regents of the University of California, Universite Claude Bernard-Lyon 1, Institut d'Enseignement Superieur et de Recherche en Alimentation, Sante Animale, Sciences Agronomiq, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Pierre MIOSSEC, Saw-See HONG, Gary FIRESTEIN
  • Patent number: 9421281
    Abstract: The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: August 23, 2016
    Assignees: Centre National de la Recherche Scientifique, Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut National de la Sante et de la Recherche Medicale (INSERM), The Joseph Fourier University of Grenoble
    Inventors: Isabelle Texier-Nogues, Jean-Luc Coll, Pascal Dumy, Didier Boturyn, Marie Favrot
  • Patent number: 9415028
    Abstract: A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: August 16, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CHU DE BREST
    Inventors: Yehezkel Ben-Ari, Eric Lemonnier
  • Patent number: 9415094
    Abstract: Provided is an HDL comprising an agent selected from the group consisting of antiproteases, antioxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use in methods of reducing side effects associated with administration of tissue plasminogen activator (tPA) in subjects in need of treatment.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 16, 2016
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Olivier Meilhac
  • Patent number: 9410139
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 9, 2016
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LUDWIG INSTITUT FOR CANCER RESEARCH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoît Van Den Eynde, Sandra Morel, Cécile Bauche
  • Patent number: 9409988
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 9, 2016
    Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'Aurelle
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Patent number: 9410955
    Abstract: The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: August 9, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER—TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE de TOULOUSE
    Inventors: Catherine Seva, Catherine Do, Audrey Ferrand, Julien Palasse, Marie-Bernadette Delisle
  • Patent number: 9410152
    Abstract: At least one microRNA selected from among hsa-miR-330, hsa-miR-7 and hsa-miR-137, the mature forms thereof, and the precursors thereof, for depigmenting the skin, and an in vitro method for identifying depigmenting compounds, which includes the steps of: a) placing at least one test compound in contact with a sample of melanocytes; b) measuring the expression or activity of at least one microRNA selected from among miR-330, miR-7 and miR-137, the mature forms thereof, and the precursors thereof, in the melanocytes; c) selecting the compounds for which at least 20% activation of the expression or of the activity of at least one of the microRNAs is measured in the melanocytes treated in a) by an element for comparing with the untreated melanocytes.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: August 9, 2016
    Assignees: CHANEL PARFUMS BEAUTE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Gaelle Saintigny, Christian Mahe, Lionel Larue, Florian Rambow
  • Publication number: 20160220224
    Abstract: The method of characterizing an ultrasound lesion (T) in organic tissues, the lesion being made by applying high intensity focused ultrasound delivered by a probe having its emission surface presenting a shape that is toroidal, consists in: after a period of at least two days from the end of ultrasound application, acquiring at least one characterization image (Ic) of the organic tissues; detecting the presence of a contrast border (16) in the characterization image (Ic); and from the contrast border (16), determining the extent of the ultrasound lesion.
    Type: Application
    Filed: October 7, 2014
    Publication date: August 4, 2016
    Applicants: EDAP TMS FRANCE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE)
    Inventors: David MELODELIMA, Jeremy VINCENOT, Emmanuel BLANC
  • Patent number: 9403039
    Abstract: A method of treating an ocular pathology by generating high intensity focused ultrasound onto at least one eye's area, the method comprises at least the following steps of: positioning onto the eye a device capable of directing high intensity focused ultrasound onto at least one annular segment, and generating high intensity focused ultrasound energy onto the segment to treat at least one annular segment in the eye. Another embodiment of the invention concerns a device for treatment of an ocular pathology comprising at least one eye ring wherein the proximal end of the eye ring is suitable to be applied onto the globe and a high intensity focused ultrasound beam generator to generate ultrasound beam fixed on the distal end of the eye ring capable of treating the whole circumference of the eye in one step.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: August 2, 2016
    Assignees: EYE TECH CARE, INSTITUIT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabrizio Romano, Cyril Lafon, Jean-Yves Chapelon, Francoise Chavrier, Alain Birer
  • Patent number: 9402821
    Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: August 2, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris-Est Creteil Val de Marne, Assistance Publique-Hopitaux de Paris
    Inventors: Agathe Tarze, Pascale Fanen
  • Publication number: 20160206579
    Abstract: The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.
    Type: Application
    Filed: March 8, 2016
    Publication date: July 21, 2016
    Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventor: Serge PICAUD
  • Publication number: 20160201128
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 14, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Patent number: 9389233
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: July 12, 2016
    Assignees: Institute National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Assistance Publique-Hopitaux de Paris, Centre Henri Becquerel, Universite Paris Descartes, Universite Pierre et Marie Curie (PARIS 6), Universite Paris-Sud
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • Publication number: 20160194623
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: December 17, 2015
    Publication date: July 7, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Caen Basse Normandie
    Inventors: Denis VIVIEN, Jerome PARCQ
  • Patent number: 9381250
    Abstract: The present inventions relates to beads as biocompatible material adapted for use within the human or animal body. Said beads are highly useful for tissue engineering, in situ tissue regeneration, as well as for drug and/or cells delivery. In addition, said beads may support biotechnological applications such as cell carriers.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: July 5, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot—Paris 7
    Inventors: Didier Letourneur, Catherine Le Visage, Sidi Mohammed Derkaoui